AMLX vs. NVCT, FGEN, SYRS, SGMT, PDSB, DMAC, RPTX, KPTI, VTGN, and ACET
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Nuvectis Pharma (NVCT), FibroGen (FGEN), Syros Pharmaceuticals (SYRS), Sagimet Biosciences (SGMT), PDS Biotechnology (PDSB), DiaMedica Therapeutics (DMAC), Repare Therapeutics (RPTX), Karyopharm Therapeutics (KPTI), Vistagen Therapeutics (VTGN), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.
95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 38.8% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Amylyx Pharmaceuticals currently has a consensus price target of $32.67, indicating a potential upside of 1,592.57%. Nuvectis Pharma has a consensus price target of $21.00, indicating a potential upside of 226.59%. Given Amylyx Pharmaceuticals' higher possible upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Nuvectis Pharma.
Amylyx Pharmaceuticals has a net margin of 12.94% compared to Nuvectis Pharma's net margin of 0.00%. Amylyx Pharmaceuticals' return on equity of 12.39% beat Nuvectis Pharma's return on equity.
In the previous week, Nuvectis Pharma had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Nuvectis Pharma and 5 mentions for Amylyx Pharmaceuticals. Nuvectis Pharma's average media sentiment score of 1.03 beat Amylyx Pharmaceuticals' score of 0.39 indicating that Nuvectis Pharma is being referred to more favorably in the news media.
Amylyx Pharmaceuticals has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.
Amylyx Pharmaceuticals received 16 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 88.89% of users gave Nuvectis Pharma an outperform vote while only 63.16% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Amylyx Pharmaceuticals beats Nuvectis Pharma on 10 of the 17 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
